Theriva Biologics, Inc. Operating Lease Liability
Theriva Biologics, Inc. (TOVX) had Operating Lease Liability of $1.90 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability $1.90M.
- 2026-03-31: Operating Lease, Liability $2.03M.
- 2025-12-31: Operating Lease, Liability $901.00K.
- 2025-09-30: Operating Lease, Liability $1.05M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $1.90M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.03M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $901.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.20M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.30M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.41M 10-K · filed 2025-03-06 |
| 2024-09-30 | $1.58M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $1.68M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.80M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.93M 10-K · filed 2024-03-25 |
| 2023-09-30 | $2.01M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $2.14M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $2.24M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $1.40M 10-K · filed 2023-03-30 |
| 2022-09-30 | $1.40M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.43M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.48M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $1.53M 10-K · filed 2022-03-16 |
| 2021-09-30 | $1.58M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $1.62M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $405.00K 10-Q · filed 2021-05-05 |
| 2020-12-31 | $473.00K 10-K · filed 2021-03-04 |
| 2020-09-30 | $539.00K 10-Q · filed 2020-11-10 |
| 2020-06-30 | $602.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $663.00K 10-Q · filed 2020-05-05 |
| 2019-12-31 | $722.00K 10-K · filed 2020-02-20 |
| 2019-09-30 | $780.00K 10-Q · filed 2019-11-04 |
| 2019-06-30 | $834.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $887.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |